JPMorgan Chase & Co. Reaffirms Underweight Rating for Replimune Group (NASDAQ:REPL)

Key Points

• JPMorgan Chase reaffirmed an underweight rating on Replimune, and analysts collectively have an average "Reduce" consensus with an average price target of $6.13.
• Shares recently opened near $4.77 (52‑week range $2.68–$13.24) and the company reported Q4 EPS of ($0.77), beating estimates of ($0.85); market cap is roughly $394 million.
• Insider Christopher Sarchi sold 6,500 shares under a Rule 10b5‑1 plan (insiders own 5.20%), while institutional investors/hedge funds hold about 92.53% of the stock and several funds increased their positions.

Replimune Group (NASDAQ:REPL - Get Free Report)'s stock had its "underweight" rating reissued by stock analysts at JPMorgan Chase & Co. in a note issued to investors on Monday,Benzinga reports.

REPL has been the subject of a number of other research reports. Wedbush upped their price objective on shares of Replimune Group from $18.00 to $19.00 and gave the company an "outperform" rating in a research note on Wednesday, February 4th. HC Wainwright reaffirmed a "sell" rating on shares of Replimune Group in a research note on Monday. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Replimune Group in a research note on Monday, December 29th. Finally, Piper Sandler cut shares of Replimune Group from an "overweight" rating to a "neutral" rating and set a $4.00 price objective for the company. in a research note on Friday. Two equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and four have issued a Sell rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Reduce" and an average price target of $6.13.

Replimune Group Price Performance

Shares of Replimune Group stock opened at $4.77 on Monday. Replimune Group has a 52-week low of $2.68 and a 52-week high of $13.24. The stock has a market capitalization of $393.94 million, a price-to-earnings ratio of -1.39 and a beta of 0.74. The company has a fifty day moving average of $7.51 and a 200-day moving average of $7.95. The company has a debt-to-equity ratio of 0.33, a quick ratio of 5.60 and a current ratio of 5.60.

Replimune Group (NASDAQ:REPL - Get Free Report) last announced its quarterly earnings data on Tuesday, February 3rd. The company reported ($0.77) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.85) by $0.08. Equities research analysts expect that Replimune Group will post -2.97 EPS for the current year.

Insider Buying and Selling

In related news, insider Christopher Sarchi sold 6,500 shares of the company's stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $8.01, for a total transaction of $52,065.00. Following the completion of the sale, the insider directly owned 151,588 shares in the company, valued at $1,214,219.88. This represents a 4.11% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.20% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. RTW Investments LP increased its position in Replimune Group by 11.6% during the 4th quarter. RTW Investments LP now owns 7,140,352 shares of the company's stock valued at $69,404,000 after purchasing an additional 744,620 shares during the period. Fcpm Iii Services B.V. increased its position in Replimune Group by 6.4% during the 3rd quarter. Fcpm Iii Services B.V. now owns 4,158,368 shares of the company's stock valued at $17,424,000 after purchasing an additional 248,672 shares during the period. State Street Corp increased its position in Replimune Group by 26.3% during the 4th quarter. State Street Corp now owns 3,693,107 shares of the company's stock valued at $35,897,000 after purchasing an additional 768,982 shares during the period. Vanguard Group Inc. increased its position in Replimune Group by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 3,479,395 shares of the company's stock valued at $14,579,000 after purchasing an additional 9,707 shares during the period. Finally, Braidwell LP increased its position in Replimune Group by 550.3% during the 3rd quarter. Braidwell LP now owns 2,750,092 shares of the company's stock valued at $11,523,000 after purchasing an additional 2,327,205 shares during the period. 92.53% of the stock is owned by hedge funds and other institutional investors.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company's proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune's lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.